US 12,103,936 B2
Crystal form of hepatitis B surface antigen inhibitor
Yanbin Hu, Shanghai (CN); Fei Sun, Shanghai (CN); Shenyi Shi, Shanghai (CN); Yanxiao Su, Shanghai (CN); and Charles Z. Ding, Shanghai (CN)
Assigned to FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD., Fujian (CN)
Appl. No. 17/293,479
Filed by FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD., Fujian (CN)
PCT Filed Nov. 22, 2019, PCT No. PCT/CN2019/120169
§ 371(c)(1), (2) Date May 13, 2021,
PCT Pub. No. WO2020/103924, PCT Pub. Date May 28, 2020.
Claims priority of application No. 201811399514.3 (CN), filed on Nov. 22, 2018.
Prior Publication US 2022/0017536 A1, Jan. 20, 2022
Int. Cl. C07D 498/04 (2006.01)
CPC C07D 498/04 (2013.01) [C07B 2200/13 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A crystal form A of a compound represented by formula (I), wherein the crystal form A has a X-ray powder diffraction pattern comprising characteristic diffraction peaks with the following angles 2θ: 8.04°±0.2°, 16.52°±0.2° and 19.52°±0.2°,

OG Complex Work Unit Chemistry